Phosphodiesterase 4 inhibitors have only marginal benefits for people with COPD, review suggests
Tuesday, May 10, 2011 - 21:30
in Health & Medicine
Giving patients with chronic obstructive pulmonary disease (COPD) newly available oral phosphodiesterase 4 inhibitors, roflumilast or cilomilast, improves lung function and reduces the likelihood of a flareup, but does not increase general quality of life, according to a systematic review.